A panel discussion of controversies and challenges in the adjuvant treatment of colon cancer

被引：0

作者：

Eduardo D.-R.G. ^{[1
]}

Esteve A.A. ^{[2
]}

Torres A.A. ^{[3
]}

Aguilar E.A. ^{[4
]}

Orgaz M.B. ^{[5
]}

Mena A.C. ^{[6
]}

Ruipérez A.C. ^{[7
]}

Batle J.F. ^{[8
]}

Alfonso P.G. ^{[9
]}

Foncillas J.G. ^{[10
]}

Castro C.G. ^{[11
]}

García M.N. ^{[12
]}

Herrero F.R. ^{[13
]}

Caturla J.M.T. ^{[14
]}

机构：

[1] Service of Medical Oncology, Hospital Universitario San Carlos, Madrid

[2] Service of Medical Oncology, Hospital Universitari Germans Trias i Pujol. Badalona, Barcelona

[3] Service of Medical Oncology, Hospital Miguel Servet, Zaragoza

[4] Service of Medical Oncology, Hospital Reina Sofía, Córdoba

[5] Service of Medical Oncology, Hospital General Carlos Haya, Málaga

[6] Service of Medical Oncology, Hospital General Universitario de Elche, Elche. Alicante

[7] Service of Medical Oncology, Hospital Clínico Universitario, Valencia

[8] Service of Medical Oncology, Ciudad Sanitaria la Paz, Madrid

[9] Service of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid

[10] Laboratory of Biotechnology and Pharmacogenomics, Clínica Universitaria de Navarra, Pamplona

[11] Service of Medical Oncology, Hospital Universitario, Madrid

[12] Service of Medical Oncology, Institut Català D'Oncologia (ICO), L'Hospitalet de Llobregat, Barcelona

[13] Service of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander

[14] Service of Medical Oncology, Hospital General Vall D'Hebron, Barcelona

来源：

Clinical and Translational Oncology | 2005年 / 7卷 / 1期

关键词：

Adjuvant treatment; Colon cancer;

D O I：

10.1007/BF02710019

中图分类号：

学科分类号：

摘要：

Current issues of adjuvant therapy for colon cancer concern the introduction of drugs other than fluorouracil-5/leucovorin (5-FU/LV), the benefits for stage II patients, the use of new primary endpoints and the influence of age on treatment benefits. These issues were addressed in a panel discussion and the conclusions were the following: FOLFOX4 is the first regimen that shows superiority over 5-FU/LV. The use of 3-year disease-free survival as primary endpoint could encourage the quicker adoption of improved therapeutic strategies into clinical practice. Available data suggest that there are some benefits for stage II patients, and the decision needs to be individualised for each patient. Further, therapeutic decisions based solely on the patient's age are inappropriate, and geriatric assessment tools will help in making this decision. This information would improve patient and physician understanding of the recent data regarding the potential benefits of adjuvant therapy.

引用

页码：3 / 11

页数：8

共 50 条

[1] Current controversies in the adjuvant therapy of colon cancer
Sobrero, A
Gughelmi, A
[J]. ANNALS OF ONCOLOGY, 2004, 15 : 39 - 41
[2] TREATMENT TECHNIQUES AND CONTROVERSIES - PANEL DISCUSSION 2
MARTINEZPINEIRO, JA
LAMM, DL
PAGANO, F
MORALES, A
RATLIFF, TL
STEG, A
JAKSE, G
[J]. EUROPEAN UROLOGY, 1992, 21 : 43 - 44
[3] Adjuvant treatment of colon cancer
Hohenberger, Werner
[J]. CHIRURG, 2006, 77 (12): : A2 - A7
[4] Adjuvant treatment of colon cancer
Bleiberg, H
[J]. CURRENT OPINION IN ONCOLOGY, 2005, 17 (04) : 381 - 385
[5] Controversies in the adjuvant treatment of breast cancer: new adjuvant endocrine treatment strategies
D'Hondt, V
Piccart, M
[J]. ANNALS OF ONCOLOGY, 2004, 15 : 23 - 29
[6] PANEL DISCUSSION ON COLON
LICHTENSTEIN, ME
ROSI, PA
PORTES, C
TARLOW, LS
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 1963, 40 (01): : 41 - &
[7] Personalized Adjuvant Treatment of Colon Cancer
Taghizadeh, Hossein
Prager, Gerald W.
[J]. VISCERAL MEDICINE, 2020, 36 (05) : 397 - 406
[8] ADJUVANT TREATMENT OF COLON-CANCER
TAYLOR, I
[J]. EUROPEAN JOURNAL OF CANCER, 1994, 30A (05) : 579 - 580
[9] Oxaliplatin in the Adjuvant Treatment of Colon Cancer
Yothers, Greg
[J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2012, 62 (01) : 3 - 4
[10] Adjuvant treatment in colon cancer - Introduction
Van Cutsem, E
[J]. EJC SUPPLEMENTS, 2005, 3 (03): : 261 - 261

← 1 2 3 4 5 →